You are here:
ketoprofen / omeprazole (Axorid)
Advice
following a re-submission
ketoprofen/omeprazole (Axorid) is accepted for use within NHS Scotland.
Licensed indication under review: the symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers, duodenal ulcers and gastroduodenal erosions in whom continued treatment with ketoprofen is essential.
Studies in healthy volunteers demonstrated the bioequivalence of this combination product to the reference products, modified-release ketoprofen and omeprazole.
Other nonsteroidal anti-inflammatory drugs can be co-prescribed with proton pump inhibitors at lower cost.
Drug Details
| Drug Name: | ketoprofen / omeprazole (Axorid) |
|---|---|
| SMC Drug ID: | 606/10 |
| Manufacturer: | Meda Pharmaceuticals Ltd |
| Indication: | For symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients who have a history or are at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers, duodenal ulcers and gastroduodenal erosions, and in whom continued treatment with ketoprofen is essential. |
| BNF Category: | |
| Sub Category: | 10.1 Drugs used in rheumatic diseases and gout |
| Submission Type: | Resubmission |
| Status: | Accepted |
| Date Advice Published: | 12 July 2010 |
Archived Advice
| ketoprofen / omeprazole (Axorid) | Full submission | 8 March 2010 |